Jim Tananbaum's most recent trade in Kinnate Biopharma Inc was a trade of 1,550,956 Common Stock done at an average price of $2.8 . Disclosure was reported to the exchange on May 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc | Jim Tananbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.80 per share. | 08 May 2023 | 1,550,956 | 3,525,957 | - | 2.8 | 4,342,677 | Common Stock |
| Kinnate Biopharma Inc | Jim Tananbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.80 per share. | 08 May 2023 | 229,044 | 520,711 | - | 2.8 | 641,323 | Common Stock |
| Kinnate Biopharma Inc | Jim Tananbaum | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 17 Feb 2023 | 1,100,000 | 1,975,001 | - | - | Common Stock | |
| Kinnate Biopharma Inc | Jim Tananbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | Jim Tananbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 17,245 | 17,245 | - | - | Stock Option (Right to Buy) |